Log in with your email address username.


[Department of Error] Department of Error

Aletaha D, Bingham CO 3rd, Tanaka Y, et al. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. Lancet 2017; 389: 1206–17—In table 1 of this Article, the n (%) of female patients in the group assigned to 100 mg sirukumab every 2 weeks should be 240 (82%), the mean BMI for placebo should be 28·72, and the units for C-reactive protein should be mg/L.